Sionna’s strategic plan includes a Phase 2a trial for SION-719 to assess its efficacy when combined with existing treatments. The company also plans to evaluate SION-451 in combination studies ...

Sionna Therapeutics has marked its presence in the pharmaceutical industry with a focus on innovative treatments. While the annual meeting outcomes signify continued stability in the company’s ...

The small molecule CFTR modulators market targets cystic fibrosis treatment, driven by innovative therapies, rising prevalence ...

Read about Sionna Therapeutics Inc (SION:XNAS) stock and today's latest news and financial updates.

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic fibrosis (CF), which offer a different mechanism to those sold by market ...

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a ...

Sionna Therapeutics, Inc. (SION) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Review the current valuation for Sionna Therapeutics Inc (SION:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 million Series B in 2022.

Sionna Therapeutics Prices Upsized Initial Public Offering BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on ...